Physician profile
Guy A Rogers
NPI 1871567545
$10,764.84
in general payments reported to CMS, 2019-2025
22 companies · $1,099 in 2025
The $1,099 reported for 2025 was more than what 85% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,909 · 2022: $3,909 · 2023: $2,714 · 2024: $1,133 · 2025: $1,099.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,006 · Travel and Lodging: $940.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,006.43 |
| Travel and Lodging | $940.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $5,585.95 | 2021-2025 | Corevalve Evolut R, Na, Cg Future |
| Novartis Pharmaceuticals Corporation | $696.16 | 2021-2025 | |
| Janssen Pharmaceuticals, INC | $696.16 | 2021-2024 | Xarelto |
| Pfizer INC. | $689.64 | 2021-2025 | |
| Astrazeneca Pharmaceuticals LP | $538.13 | 2021-2025 | Farxiga, Brilinta |
| Edwards Lifesciences Corporation | $511.78 | 2022-2025 | Edwards Sapien 3 Ultra Transcatheter Heart Valve, Sapien 3 Ultra Resilia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $386.13 | 2021-2025 | Jardiance |
| Actelion Pharmaceuticals US, INC. | $346.48 | 2021-2025 | Opsumit, Uptravi |
| Amgen INC. | $207.01 | 2021-2025 | Repatha, Repatha |
| Abiomed | $172.59 | 2024-2025 | Impella |
| Abbott Laboratories | $147.08 | 2023-2025 | Mitraclip, Dragonfly Opstar, Navitor |
| Novo Nordisk INC | $139.59 | 2023-2025 | Wegovy, Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $124.18 | 2023-2025 | Camzyos, Eliquis |
| Inari Medical, INC. | $89.57 | 2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $81.10 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Chiesi USA, INC. | $76.66 | 2022-2025 | Kengreal, Cleviprex |
| Lexicon Pharmaceuticals, INC. | $73.79 | 2023-2024 | Inpefa |
| Philips North America LLC | $57.59 | 2023-2024 | (Ck7) Extended Holter |
| Scpharmaceuticals INC. | $52.09 | 2024-2025 | |
| Amarin Pharma, INC. | $51.11 | 2021 | |
| Kiniksa Pharmaceuticals International, Plc | $21.30 | 2024 | Arcalyst |
| Bridgebio Pharma, INC. | $20.75 | 2025 | Attruby |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Guy Rogers listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.